MGRC retains sole and exclusive ownership of the MGRC Content, including all intellectual property and proprietary rights, title and interests subsisting therein. You agree not to remove any copyright, trademark, or other proprietary notice forming part of the Content or exploit any part thereof without the express permission from MGRC in respect of the MGRC...
MGRC does not in any way control or endorse the Third Party Content. As such, MGRC shall not be responsible for the accuracy, completeness, legality, legitimacy or any other aspect of the files, data and information forming part of Third Party Content and MGRC is not in a position to ensure that You will be...
Please confirm all Content provided in the Portal with Your physician and healthcare provider, as well as with other sources. MGRC does not guarantee or warrant the recommendation, diagnosis, therapy, treatment, medication, device, action or strategy of any person mentioned throughout or in relation to the Content. The Content is for informational purposes only and...
Your use of the Portal allows You to access the Content. You may print out copies of the Content for private and individual use only, but You may not remove any copyright, trademark or other proprietary notices forming any part of the Content. You are solely responsible for the use of the Content and agree...
By visiting the Portal, You are deemed to have accepted these Terms & Conditions governing the use of this site and Your access to the Content herein. You acknowledge MGRC reserves the right to revise these Terms & Conditions at any time. MGRC will post the latest version of these Terms & Conditions via the...
“Services” means the services available on the Portal. “You/Your” refers to you, the end user of the Portal. “Terms & Conditions” means these Terms and Conditions of Use and future amendments hereto. “MGRC Content” means all content available on the Portal, including but not limited to all text, images, data, software applications, logos and publications...
T-Cell Cryopreservation Option If any of the above requirements are not met for the patient to be eligible to undergo the CAR T-Cell immunotherapy for the time being, there is an option for the patient to freeze their T- Cells for future use once treatment can proceed.
Cytopenia – Cytopenia occurs when one or more of the blood cell types are lower than it should be. Blood consists of red blood cells which carry oxygen and nutrients around the body, and white blood cells which fight infection. B-Cell Aplasia – B-Cell aplasia occurs when anti-CD19 CAR T-Cells kill normal B lymphocytes that...
Patients must meet the following criteria to be eligible for CAR T-Cell Immunotherapy: Patient is well enough to receive CAR T-Cell Immunotherapy. Tumour has expressed the appropriate marker, e.g. CD19. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Absence of disease complications or chemo-toxicity; such as, infection, active GVHD, hyperleucocytosis, severe...
Chemotherapy, surgery and radiotherapy are USFDA-approved treatments that have long been used as primary and secondary treatments for cancer. However, when cancer recurs in the future, or when these primary and secondary treatments are unable to reduce or kill cancer, then doctors and patients may opt for other types of treatments including immunotherapy and also...
Sign up for you and your loved ones to receive the latest news and updates about CAR T-Cell Immunotherapy.
